SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies
E Begier, DJ Seiden, M Patton, E Zito, J Severs… - Vaccine, 2017 - Elsevier
E Begier, DJ Seiden, M Patton, E Zito, J Severs, D Cooper, J Eiden, WC Gruber, KU Jansen…
Vaccine, 2017•ElsevierBackground Staphylococcus aureus is a leading cause of healthcare-associated infections.
No preventive vaccine is currently licensed. SA4Ag is an investigational 4-antigen S. aureus
vaccine, composed of capsular polysaccharide conjugates of serotypes 5 and 8 (CP5 and
CP8), recombinant surface protein clumping factor A (rmClfA), and recombinant manganese
transporter protein C (rMntC). This Phase 1 study aimed to confirm the safety and
immunogenicity of SA4Ag produced by the final manufacturing process before efficacy study …
No preventive vaccine is currently licensed. SA4Ag is an investigational 4-antigen S. aureus
vaccine, composed of capsular polysaccharide conjugates of serotypes 5 and 8 (CP5 and
CP8), recombinant surface protein clumping factor A (rmClfA), and recombinant manganese
transporter protein C (rMntC). This Phase 1 study aimed to confirm the safety and
immunogenicity of SA4Ag produced by the final manufacturing process before efficacy study …
Background
Staphylococcus aureus is a leading cause of healthcare-associated infections. No preventive vaccine is currently licensed. SA4Ag is an investigational 4-antigen S. aureus vaccine, composed of capsular polysaccharide conjugates of serotypes 5 and 8 (CP5 and CP8), recombinant surface protein clumping factor A (rmClfA), and recombinant manganese transporter protein C (rMntC). This Phase 1 study aimed to confirm the safety and immunogenicity of SA4Ag produced by the final manufacturing process before efficacy study initiation in a surgical population.
Methods
Healthy adults (18–<65 years) received one intramuscular SA4Ag injection. Serum functional antibodies were measured at baseline and Day 29 post-vaccination. An opsonophagocytic activity (OPA) assay measured the ability of vaccine-induced antibodies to CP5 and CP8 to kill S. aureus clinical isolates. For MntC and ClfA, antigen-specific immunogenicity was assessed via competitive Luminex® immunoassay (cLIA) and via fibrinogen-binding inhibition (FBI) assay for ClfA only. Reactogenicity and adverse event data were collected.
Results
One hundred participants were vaccinated. SA4Ag was well tolerated, with a satisfactory safety profile. On Day 29, OPA geometric mean titers (GMTs) were 45,738 (CP5, 95% CI: 38,078–54,940) and 42,652 (CP8, 95% CI: 32,792–55,477), consistent with 69.2- and 28.9-fold rises in bacteria-killing antibodies, respectively; cLIA GMTs were 2064.4 (MntC, 95% CI: 1518.2–2807.0) and 3081.4 (ClfA, 95% CI: 2422.2–3920.0), consistent with 19.6- and 12.3-fold rises, respectively. Similar to cLIA results, ClfA FBI titers rose 11.0-fold (GMT: 672.2, 95% CI: 499.8–904.2). The vast majority of participants achieved the pre-defined biologically relevant thresholds: CP5: 100%; CP8: 97.9%, ClfA: 87.8%; and MntC 96.9%.
Conclusions
SA4Ag was safe, well tolerated, and rapidly induced high levels of bacteria-killing antibodies in healthy adults. A Phase 2B efficacy trial in adults (18–85 years) undergoing elective spinal fusion is ongoing to assess SA4Ag’s ability to prevent postoperative invasive surgical site and bloodstream infections caused by S. aureus.
Clinicaltrials.gov Identifier: NCT02364596.
Elsevier